FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial
Description
CONCLUSIONS: In this unique-dosing-regimen study, FX06 did not lower SARS-CoV-2-induced pulmonary vascular leakage. Future investigations will need to evaluate its efficacy at earlier times during the disease or using other regimens. Trial
